The global irritable bowel syndrome with constipation (IBS-C) drug market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include the rise in the geriatric population, increase in the prevalence of gastrointestinal diseases such as constipation, the surge in level of stress, and unhealthy diet. Moreover, some other factors that are expected to fuel the market growth include an increase in awareness programs regarding the treatment and management of IBS and a surge in inclination toward IBS products that enhance therapeutic outcomes. Furthermore, the untapped potential opportunity across developing economies presents lucrative opportunities for the growth of the market during the forecast period.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. Signs & symptoms include abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Treatment of irritable bowel syndrome consists of stress relief, change in diet, proper medicines, and counseling. Medications available for the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used for the treatment of irritable bowel syndrome, which includes dicyclomine, peppermint oil, and hyoscyamine. In addition, an increase in the prevalence of gastrointestinal diseases such as constipation and diarrhea due to changes in lifestyles, an increase in the geriatric population, a surge in uptake of drugs such as linaclotide and lubiprostone, and a rise in patient awareness toward the treatment of irritable bowel syndrome are some other factors that will propel the growth of the global IBS-C drug market during the forecast period.
To Request a Sample of our Report on Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market: https://www.omrglobal.com/request-sample/ibs-c-drug-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Drug Type
- By Prescription Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Catalent Pharma Solutions, Inc., AstraZeneca plc, and Abbott Laboratories, among others.
IBS-C Drug Market Report by Segment
By Drug Type
- Lubiprostone
- Linaclotide
- Stimulant Laxatives
- Osmotic Laxatives
- Others
By Prescription Type
- Prescription Drugs
- Over-the-Counter Drugs
A full Report of Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market is Available @ https://www.omrglobal.com/industry-reports/ibs-c-drug-market
IBS-C Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
